Belvedere Trading’s Amneal Pharmaceuticals AMRX Stock Holding History

Belvedere Trading’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,161	Closed	-$106K	–	360
2022 Q1	$106K	Buy	+25,161	New	+$111K	﹤0.01%	319

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belvedere Trading's AMRX Position: Q2 2022 in Review

Belvedere Trading sold out of Amneal Pharmaceuticals (AMRX) in Q2 2022, closing a stake of 25,161 shares — an estimated $106K sold.

Belvedere Trading first reported a position in AMRX in Q1 2022 and held it in 1 quarter. The position peaked at $106K in Q1 2022. 153 funds tracked by Wall St. Rank hold AMRX as of Q2 2022.

Belvedere Trading reported no remaining Amneal Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Belvedere Trading sold 25,161 Amneal Pharmaceuticals shares in Q2 2022, an estimated $106K.
Belvedere Trading first reported a position in Amneal Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Belvedere Trading's Amneal Pharmaceuticals position peaked at $106K in Q1 2022.
153 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2022.

Based on Belvedere Trading's 13F filing for Q2 2022, filed 21 Jul 2022.